There has been confusion andmisunderstandings about vaccines. But vaccinations are an important part offamily and public health. Vaccines prevent the spread of contagious, dangerous,and deadly diseases.
The world's famous medical journal 'Lancet'has been stamped on the effectiveness and safety of this indigenous vaccinemade in India, Covaxin. The medical journal stated that phase three data of thevaccine demonstrated a 77.8 percent efficacy against symptomatic COVID-19 andalso a 70.8 percent protection against all variants of SARS-CoV-2 virus.
The main findings from thejournal state that:
• Covaxin shows a 77.8 percent efficacy against symptomatic COVID-19 anda 63.6 percent protection against asymptomatic COVID-19
• The analysis demonstrates Covaxin to be 93.4 percent effectiveagainst severe symptomatic COVID-19
• Covaxin demonstrates a 65.2 percent efficacy against the easilytransmissible Delta variant of coronavirus
• Efficacy data demonstrates 70.8 percent protection against allvariants of SARS-CoV-2 virus
Dr. Krishna Ella, CMD of BharatBiotech said, “The peer-review of Covaxin phase III clinical trial data in TheLancet, an authoritative voice in global medicine, validates our commitment todata transparency and meeting the stringent peer-review standards ofworld-leading medical journals. This accomplishment reflects the undeterredcommitment by my team members at Bharat Biotech, our public partners, IndianCouncil of Medical Research, National Institute of Virology, and the trustimposed by our trial participants who made this happen.”
Also read: Two Zika virus cases found in UP's Lucknow
Dr. Balram Bhargava, DirectorGeneral, Indian Council of Medical Research (ICMR) said, "I am delightedto see that the phase III efficacy data has also been published in The Lancet,one of the most reputed journals worldwide. This itself speaks highly about thestrong position of Covaxin amongst other global front-runners Covid-19vaccines. The bench to bedside journey of Covaxin in less than 10 monthsshowcases the immense strength of “Atmanirbhar Bharat” along with the Indianacademia and industry in fighting against the odds and carving a niche in theglobal community.”